On September 16, Illumina rose 5.42% in regular trading, trading at $234.27 per share, with turnover of approximately $73.46 million. The rally was driven by a confluence of bullish catalysts including a significant analyst upgrade and a major index inclusion event.

UBS recently upgraded Illumina from Neutral to Buy, raising its price target sharply from $135 to $260, well above the analyst consensus target of $193.61, sending a strong bullish signal. Separately, S&P Dow Jones Indices announced that Illumina will officially join the S&P 500 index before the open on September 21 as part of the quarterly rebalance. The upcoming inclusion is expected to generate mandatory buying demand from passive index-tracking funds, providing additional near-term support. RBC Capital Markets also noted that Illumina's clinical sequencing revenue could sustain mid-teens growth, with competitive concerns fading.

Fundamentally, Illumina reported Q2 adjusted EPS of $1.31, beating the $1.23 estimate, with revenue of $1.159 billion also exceeding the $1.130 billion consensus. The board previously authorized an additional $1.5 billion in stock buybacks.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)